Pyrazolopyridinone compounds

A compound of formula (I):

• or a tautomeric or stereochemically isomeric form thereof, wherein:
• A1, A2 and A3 each independently are CH, CRa or N, provided that maximum two of A1, A2 and A3 are CRa;
• C1 is hydrogen or C1-4alkyl;
• C2 is hydrogen, C1-4alkyl, hydroxyl or C1-4alkoxy;
• or C1 and C2 are taken together to form a C3-6cycloalkyl together with the carbon atom to which they are attached;
• Y is a direct bond, —O—, C(═O), NRy, S(═O)2, or C1-4alkyl;
• Ry is hydrogen or C1-4alkyl;
• each Ra independently is C1-6alkyl, haloC1-6alkyl, halo, C1-6alkoxy, carboxyl, C1-6alkyl-oxycarbonyl, C2-6alkenyl, C2-6alkynyl, cyano, cyanoC1-6alkyl, hydroxyC1-6alkyl, —C(═O)—NH2, —C(═O)—NH(C1-4alkyl), —C(═O)—N(C1-4alkyl)2, or a 3 to 6 membered monocyclic saturated heterocyclyl containing at least one heteroatom that is N, O or S;
• Rb is hydrogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, C1-6alkyloxycarbonyl, C2-6alkenyl, C2-6alkynyl, cyanoC1-6alkyl, hydroxyC1-6alkyl, —C(═O)—NH2, —C(═O)—NH(C1-4alkyl), —C(═O)—N(C1-4alkyl)2, C3-6cycloalkyl, phenyl, a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom that is N, O or S, or C1-6alkyl substituted with C3-6cycloalkyl or with phenyl or with a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom that is N, O or S;
• D is a 3 to 12 membered heterocyclyl containing at least one heteroatom that is N, O or S, wherein said heterocyclyl is optionally substituted with 1 to 5 Rc substituents;
• each Rc independently is oxo, halo, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyl, haloC1-6alkyl, haloC1-6alkyloxy, carboxyl, HOOC—C1-6alkyl-, C1-6alkyl substituted with —C(═O)—O—C1-6alkyl, C1-6alkyl-O—C(═O)—, cyano, cyanoC1-6alkyl, C1-6alkyl-C(═O)—, —SO2—C1-6alkyl, C3-6cycloalkyl, phenyl, a 3 to 6 membered monocyclic saturated heterocyclyl containing at least one heteroatom that is N, O or S, or a 5 or 6 membered monocyclic aromatic heterocyclyl containing at least one heteroatom that is N, O or S;
• B is a 3 to 12 membered carbocyclyl or a 3 to 12 membered heterocyclyl containing at least one heteroatom that is N, O or S, wherein said carbocyclyl and heterocyclyl are each optionally substituted with 1 to 5 R substituents;
• each R independently is C1-6alkyl, cyano, halo, C1-6alkoxy, haloC1-6alkoxy, hydroxyl, hydroxyC1-6alkyl, haloC1-6alkyl, oxo, —SO2—NH2, —SO2—NH(C1-4alkyl), —SO2—N(C1-4alkyl)2, —NH—C(═O)—C2-6alkenyl, —C(═O)—C1-6alkyl, —C(═O)—C2-6alkenyl, C1-6alkyl-O—C(═O)—, C3-6cycloalkyl, phenyl, or a 3 to 6 membered monocyclic heterocyclyl containing at least one heteroatom that is N, O or S;
• or a pharmaceutically acceptable salt thereof or a solvate thereof.